Pursuing Charlene's Dream

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Approximately one-third of patients with pancreatic cancer and anxiety had a palliative care consultation, data showed.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors.

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an expert said.